SEP 23, 2020 6:30 AM PDT

Mass Cytometry in Translational Research: Session I

Speakers

Abstract

Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML

6:30–7:00 am PDT

Presented By: Shelley Herbrich, PhD

The mechanisms of resistance to immunotherapies in patients with acute myeloid leukemia (AML) are not well-characterized, and biomarkers for improved immunotherapeutic strategies are critical. In this presentation, we characterize the baseline immune landscape and potential mechanisms of resistance using single-cell CyTOF mass cytometry profiling of serially collected samples from refractory/relapsed AML patients undergoing therapy with hypomethylating agents combined with PD-L1 inhibition. Single-cell characterization of these primary bone marrow samples reveals novel insights into the immune checkpoint distribution on AML cells while simultaneously allowing for the evaluation of T cell composition and fitness.

 

Understanding CD19 negative relapse following CAR T therapies in acute lymphoblastic leukemia

7:00–7:30 am PDT

Presented By: Kara Davis, DO

Chimeric antigen T (CAR T) cells have demonstrated impressive efficacy in refractory and relapsed B cell malignancies, including B cell lymphoblastic leukemia. However, loss of the target antigen, CD19, has been shown to be a mediator of relapse for some patients. We have used mass cytometry and single-cell RNA sequencing to understand whether rare CD19-negative cells exist for patients before they receive CAR T cells and to identify cell types and their features associated with relapse following CAR T therapy for relapsed acute lymphoblastic leukemia.

 

Mass cytometry reveals distinct immune signatures marking progression from mild to severe COVID-19

7:30–8:00 am PDT

Bernd Bodenmiller, PhD

Coronavirus disease 2019 (COVID-19) manifests with a range of severities, but immune signatures of mild and severe disease are still not fully understood. We used 40-plex mass cytometry and targeted serum proteomics to profile innate and adaptive immune cell populations from peripheral blood of patients with mild or severe COVID-19 and healthy controls. Our data provide new insights into the pathological immune responses that are likely key mechanism in severe COVID-19, further supporting investigation of targeted anti-inflammatory interventions in severe COVID-19.


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
JUL 15, 2021 8:00 AM PDT
C.E. CREDITS
JUL 15, 2021 8:00 AM PDT
Date: July 15, 2021 Time: 8:00am (PDT), 11:00am (EDT) High dimensional full spectrum flow cytometry grants unprecedented access to previously unattainable parameters in cellular biology. Flu...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
OCT 12, 2021 9:00 AM PDT
C.E. CREDITS
OCT 12, 2021 9:00 AM PDT
Date: October 12, 2021 Time: 9:00am (PDT), 12:00pm (EDT) SCIEX’s next-generation Biologics Explorer software is an innovative platform for the comprehensive and deep characterization o...
Loading Comments...
Show Resources